A study of AZD0486 plus Rituximab in previously untreated Follicular Lymphoma patients

Trial Identifier: D7401C00001
Sponsor: AstraZeneca
Start Date: August 2024
Primary Completion Date: April 2031
Study Completion Date: February 2035

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU Macquarie University, AU, 2109
AU Nedlands, AU, 6009
BE Brussels, BE, 1070
BE Brussels, BE, 1090
BE Gent, BE, 9000
BE Mechelen, BE, 2800
CA, ON Hamilton, ON, CA, L8V 5C2
CA, ON Oshawa, ON, CA, L1G 2B9
CA, QC Chicoutimi, QC, CA, G7H 5H6
CA, QC Montreal, QC, CA, H4J 1C5
CN Beijing, CN, 100142
CN Tianjin, CN, 300020
ES Barcelona, ES, 8036
ES Barcelona, ES, 08035
ES El Palmar, ES, 30120
ES Girona, ES, 17007
ES Las Palmas de Gran Canaria, ES, 35020
ES Madrid, ES, 28040
ES Madrid, ES, 28041
ES Oviedo, ES, 33011
ES Pamplona, ES, 31008
ES Santander, ES, 39008
FI Helsinki, FI, 00029
FI Kuopio, FI, 70029
FI Tampere, FI, 33520
GB London, GB, EC1M6BQ
HK Hong Kong, HK, 999077
HK Shatin, HK, 00000
HU Budapest, HU, 1122
JP Koto-ku, JP, 135-8550
JP Okayama-shi, JP, 700-8558
KR Seoul, KR, 06351
KR Seoul, KR, 05505
KR Seoul, KR, 13620
PL Gliwice, PL, 44-102
SE Falun, SE, 79182
SE Uppsala, SE, 75185
TR Ankara, TR, 6200
TR Ankara, TR, 06620
TW Changhua, TW, 50006
TW Kaohsiung city, TW, 833
TW Kaohsiung City, TW, 80756
TW Lukang Township, TW, 505029
TW Tainan City, TW, 704
TW Taipei City, TW, 106